EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report.

Frontiers in oncology(2023)

引用 1|浏览3
暂无评分
摘要
We report for the first time the long-lasting and stable disease control with Almonertinib for EGFR p.V774M/p.L833V compound mutations treatment, hoping to provide more clinical case references for the treatment of rare compound mutations.
更多
查看译文
关键词
lung adenocarcinoma,almonertinib,egfr,mutations
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要